TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Consumption of Dairy Products on Glycemic Control, Body Weight and Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Randomized Controlled Clinical Study
Brief Summary: This is a randomized prospective clinical study in patients with type 2 diabetes to evaluate the effect of dairy products with full or low fat on glycemic control and cardio-metabolic risk factors in comparison to a regular diet.


Options:
A: Intervention Type: BEHAVIORAL; Name: Intensive dietary advice; Assigned to Arm(s): N/A
B: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics
C: Arm Label: Full fat dairy group; Type: EXPERIMENTAL; Interventions: Other: Full fat dairy | Arm Label: Low fat dairy group; Type: EXPERIMENTAL; Interventions: Other: Low fat dairy | Arm Label: Control group; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Full fat dairy; Assigned to Arm(s): Full fat dairy group | Intervention Type: OTHER; Name: Low fat dairy; Assigned to Arm(s): Low fat dairy group | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control group
D: Arm Label: High MUFA diet; Type: EXPERIMENTAL; Interventions: Other: High-MUFA diet | Arm Label: High CHO diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High-CHO diet | Intervention Type: OTHER; Name: High-MUFA diet; Assigned to Arm(s): High MUFA diet | Intervention Type: OTHER; Name: High-CHO diet; Assigned to Arm(s): High CHO diet

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Consumption of Dairy Products on Glycemic Control, Body Weight and Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Randomized Controlled Clinical Study
Brief Summary: This is a randomized prospective clinical study in patients with type 2 diabetes to evaluate the effect of dairy products with full or low fat on glycemic control and cardio-metabolic risk factors in comparison to a regular diet.


Options:
A: Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A
B: Arm Label: Exercise under observation; Type: EXPERIMENTAL; Interventions: Behavioral: Modified paleolithic diet and exercise under observation | Arm Label: General advice on exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Modified paleolithic diet and general advice on exercise | Intervention Type: BEHAVIORAL; Name: Modified paleolithic diet and exercise under observation; Assigned to Arm(s): Exercise under observation | Intervention Type: BEHAVIORAL; Name: Modified paleolithic diet and general advice on exercise; Assigned to Arm(s): General advice on exercise
C: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
D: Arm Label: Full fat dairy group; Type: EXPERIMENTAL; Interventions: Other: Full fat dairy | Arm Label: Low fat dairy group; Type: EXPERIMENTAL; Interventions: Other: Low fat dairy | Arm Label: Control group; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Full fat dairy; Assigned to Arm(s): Full fat dairy group | Intervention Type: OTHER; Name: Low fat dairy; Assigned to Arm(s): Low fat dairy group | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Keratin4VLU: A Randomised Controlled Trial of Wool-derived Keratin Dressings for Venous Leg Ulcers
Brief Summary: Venous leg ulcers (VLU) are the most common leg ulcer, can be painful, and limit work, lifestyles and activity, especially in older patients. Compression bandaging is the main treatment but there are few added treatments for patients with slow healing VLU. About 50% of patients with VLU may be slow healing. Research suggests using keratin dressings as well as using compression may help healing in patients with show healing VLU, but the current evidence is not enough to change clinical practice. The investigators will conduct a randomised controlled trial to test whether using keratin dressings is better than usual care for slow healing VLU.


Options:
A: Arm Label: A - Low Q7D; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: B - Low Q14D; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: C - High Q7D; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: D - High Q14D; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: E - Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (Vehicle) | Intervention Type: BIOLOGICAL; Name: HP802-247; Assigned to Arm(s): A - Low Q7D, B - Low Q14D, C - High Q7D, D - High Q14D | Intervention Type: BIOLOGICAL; Name: Placebo (Vehicle); Assigned to Arm(s): E - Vehicle
B: Arm Label: HP802-247 plus compression therapy; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: HP802-247 Vehicle plus compression therapy; Type: PLACEBO_COMPARATOR; Interventions: Other: HP802-247 Vehicle | Intervention Type: BIOLOGICAL; Name: HP802-247; Assigned to Arm(s): HP802-247 plus compression therapy | Intervention Type: OTHER; Name: HP802-247 Vehicle; Assigned to Arm(s): HP802-247 Vehicle plus compression therapy
C: Arm Label: Keratin dressings; Type: EXPERIMENTAL; Interventions: Device: Keratin dressings | Arm Label: Usual care dressings; Type: ACTIVE_COMPARATOR; Interventions: Device: Usual care dressings | Intervention Type: DEVICE; Name: Keratin dressings; Assigned to Arm(s): Keratin dressings | Intervention Type: DEVICE; Name: Usual care dressings; Assigned to Arm(s): Usual care dressings
D: Arm Label: HP802-247; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Biological: Vehicle | Intervention Type: BIOLOGICAL; Name: HP802-247; Assigned to Arm(s): HP802-247 | Intervention Type: BIOLOGICAL; Name: Vehicle; Assigned to Arm(s): Vehicle

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dose Reduction of Antenatal Betamethasone Given to Prevent the Neonatal Complications Associated With Very Preterm Birth: a Randomized, Multicentre, Double Blind Placebo-controlled Non Inferiority Trial
Brief Summary: Extensive animal studies have indicated that antenatal betamethasone exposure results in altered developmental trajectories of several fetal systems. Follow up of a randomized controlled trial has shown that antenatal betamethasone exposure might result in insulin resistance 30 years later. Furthermore, animal studies and randomized trials in Humans have clearly demonstrated that betamethasone-induced growth alterations were dose-related.

In ewes, a 50% reduced dose regimen resulted in maximal improvement in preterm lamb lung function, similar to those obtained after a full dose.

Our hypothesis is that antenatal betamethasone after a 50% dose reduction, justified by the potential long term effects of this drug, is not inferior to a full dose to promote fetal lung maturation in Humans.


Options:
A: Arm Label: 12mg betamethasone+12mg betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: betamethasone 24 mg | Arm Label: 12 mg betamethasone+ placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 12mg betamethasone +placebo | Intervention Type: DRUG; Name: betamethasone 24 mg; Assigned to Arm(s): 12mg betamethasone+12mg betamethasone | Intervention Type: DRUG; Name: 12mg betamethasone +placebo; Assigned to Arm(s): 12 mg betamethasone+ placebo
B: Arm Label: ACS (Group 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethason Sodium Phosphate | Arm Label: Placebo (Group 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Betamethason Sodium Phosphate; Assigned to Arm(s): ACS (Group 1) | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo (Group 2)
C: Intervention Type: DRUG; Name: Betamethasone(Celestone soluspan) and Dexamethasone; Assigned to Arm(s): N/A
D: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dose Reduction of Antenatal Betamethasone Given to Prevent the Neonatal Complications Associated With Very Preterm Birth: a Randomized, Multicentre, Double Blind Placebo-controlled Non Inferiority Trial
Brief Summary: Extensive animal studies have indicated that antenatal betamethasone exposure results in altered developmental trajectories of several fetal systems. Follow up of a randomized controlled trial has shown that antenatal betamethasone exposure might result in insulin resistance 30 years later. Furthermore, animal studies and randomized trials in Humans have clearly demonstrated that betamethasone-induced growth alterations were dose-related.

In ewes, a 50% reduced dose regimen resulted in maximal improvement in preterm lamb lung function, similar to those obtained after a full dose.

Our hypothesis is that antenatal betamethasone after a 50% dose reduction, justified by the potential long term effects of this drug, is not inferior to a full dose to promote fetal lung maturation in Humans.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: betamethasone | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: betamethasone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
B: Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): N/A
C: Arm Label: 12mg betamethasone+12mg betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: betamethasone 24 mg | Arm Label: 12 mg betamethasone+ placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 12mg betamethasone +placebo | Intervention Type: DRUG; Name: betamethasone 24 mg; Assigned to Arm(s): 12mg betamethasone+12mg betamethasone | Intervention Type: DRUG; Name: 12mg betamethasone +placebo; Assigned to Arm(s): 12 mg betamethasone+ placebo
D: Arm Label: ACS (Group 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethason Sodium Phosphate | Arm Label: Placebo (Group 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Betamethason Sodium Phosphate; Assigned to Arm(s): ACS (Group 1) | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo (Group 2)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Temozolomide Plus Bevacizumab Chemotherapy in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status (KPS<70)
Brief Summary: The optimal treatment of glioblastoma multiforme (GBM) in patients aged ≥70 years with a Karnofsky performance status (KPS) \<70 is unestablished. This clinical trial evaluated the efficacy and safety of upfront temozolomide (TMZ) and bevacizumab (Bev) in patients aged ≥70 years and a KPS \<70.


Options:
A: Arm Label: O6-BG + BCNU + Radiation Therapy; Type: EXPERIMENTAL; Interventions: Drug: carmustine, Radiation: radiation therapy, Drug: O6-Benzylguanine | Arm Label: BCNU + Radiation Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: carmustine, Radiation: radiation therapy | Intervention Type: DRUG; Name: carmustine; Assigned to Arm(s): BCNU + Radiation Therapy, O6-BG + BCNU + Radiation Therapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): BCNU + Radiation Therapy, O6-BG + BCNU + Radiation Therapy | Intervention Type: DRUG; Name: O6-Benzylguanine; Assigned to Arm(s): O6-BG + BCNU + Radiation Therapy
B: Arm Label: Temozolomide and Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Temozolomide, Drug: Bevacizumab | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide and Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Temozolomide and Bevacizumab
C: Arm Label: NovoTTF-100A device in combination with Temozolomide; Type: EXPERIMENTAL; Interventions: Device: NovoTTF-100A device | Arm Label: Temozolomide alone, as the best known standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide | Intervention Type: DEVICE; Name: NovoTTF-100A device; Assigned to Arm(s): NovoTTF-100A device in combination with Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide alone, as the best known standard of care
D: Intervention Type: DRUG; Name: Radiotherapy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation Intervention for Women With HIV/AIDS
Brief Summary: As people with HIV/AIDS live longer, the burden of non-AIDS-related health problems such as cardiovascular diseases and cancers on these people have consistently increased. Smoking is one of the major contributing factors to these health problems and rates of cigarette smoking in this group are substantially higher than those of the general population: 40-70% vs. 17-10%. Especially, women living with HIV/AIDS seem to be more susceptible to the negative consequence of smoking than their male counterparts. They are also less likely to see tobacco dependence treatment for dual stigma associated with both conditions: HIV infection and nicotine addiction. This is a pilot study to develop smoking cessation intervention for these women.


Options:
A: Arm Label: Video; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Voice; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Video, Voice
B: Arm Label: Information Prescription; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking Coach | Arm Label: QUIT-PRIMO; Type: EXPERIMENTAL; Interventions: Behavioral: Decide2Quit | Intervention Type: BEHAVIORAL; Name: Decide2Quit; Assigned to Arm(s): QUIT-PRIMO | Intervention Type: BEHAVIORAL; Name: Smoking Coach; Assigned to Arm(s): Information Prescription
C: Arm Label: Enhanced PTSD Health Buddy and Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Motivation Interviewing Counseling | Arm Label: Usual PTSD Health Buddy Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivation Interviewing Counseling; Assigned to Arm(s): Enhanced PTSD Health Buddy and Motivational Interviewing
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedicine Smoking Cessation Program | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone Quitline Smoking Cessation Program | Intervention Type: BEHAVIORAL; Name: Telemedicine Smoking Cessation Program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Telephone Quitline Smoking Cessation Program; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects With Moderate-to- Severe Plaque Psoriasis
Brief Summary: The main purpose of this study is to evaluate the efficacy of the study drug mirikizumab in participants with moderate to severe plaque psoriasis.


Options:
A: Arm Label: 30 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 100 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 300 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirikizumab; Assigned to Arm(s): 100 mg Mirikizumab, 30 mg Mirikizumab, 300 mg Mirikizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: CNTO1275 (ustekinumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1275 63 mg; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo
C: Arm Label: Placebo-controlled Phase:; Type: EXPERIMENTAL; Interventions: Other: Placebo | Arm Label: Placebo-controlled Phase: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Arm Label: Extension Phase: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Extension Phase: Apremilast 30 mg, Placebo-controlled Phase: Apremilast 30 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo-controlled Phase:
D: Arm Label: UCB4940 8 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 40 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 160 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 480 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 640 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: UCB4940; Assigned to Arm(s): UCB4940 160 mg, UCB4940 40 mg, UCB4940 480 mg, UCB4940 640 mg, UCB4940 8 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects With Moderate-to- Severe Plaque Psoriasis
Brief Summary: The main purpose of this study is to evaluate the efficacy of the study drug mirikizumab in participants with moderate to severe plaque psoriasis.


Options:
A: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: ABP 501; Type: EXPERIMENTAL; Interventions: Biological: ABP 501 | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: ABP 501; Assigned to Arm(s): ABP 501
C: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A
D: Arm Label: 30 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 100 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 300 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirikizumab; Assigned to Arm(s): 100 mg Mirikizumab, 30 mg Mirikizumab, 300 mg Mirikizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects With Moderate-to- Severe Plaque Psoriasis
Brief Summary: The main purpose of this study is to evaluate the efficacy of the study drug mirikizumab in participants with moderate to severe plaque psoriasis.


Options:
A: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
B: Arm Label: Abatacept (30/10); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Abatacept (10/10); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Abatacept (3/3); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept (10/10), Abatacept (3/3), Abatacept (30/10) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 30 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 100 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 300 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirikizumab; Assigned to Arm(s): 100 mg Mirikizumab, 30 mg Mirikizumab, 300 mg Mirikizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: CNTO 1275 45 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 45 mg | Arm Label: CNTO 1275 90 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 90 mg | Arm Label: Etanercept 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept 50 mg | Intervention Type: DRUG; Name: CNTO 1275 45 mg; Assigned to Arm(s): CNTO 1275 45 mg | Intervention Type: DRUG; Name: CNTO 1275 90 mg; Assigned to Arm(s): CNTO 1275 90 mg | Intervention Type: DRUG; Name: Etanercept 50 mg; Assigned to Arm(s): Etanercept 50 mg

Answer: C